• TG Therapeutics recently reported that Briumvi exceeded expectations in clinical trials and that it has begun a Phase 2 study in treatment-resistant schizophrenia, developments that have drawn increased attention from investors and analysts.
• These clinical advances, combined with analysts’ more optimistic earnings projections, highlight how a single therapy platform may be shaping the company’s overall growth prospects.
• We’ll now examine how Briumvi’s stronger-than-expected trial results and schizophrenia trial launch may influence TG Therapeutics’ broader investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe Briumvi can sustain its role as the core revenue engine while the company carefully expands into new indications and formulations. The latest trial outperformance and schizophrenia Phase 2 start support that thesis, but they do not change the near term catalyst: subcutaneous Briumvi data. The biggest risk remains the company’s dependence on Briumvi in a crowded, pricing sensitive MS market.

The most relevant recent update here is the clinical progress on subcutaneous Briumvi, where Phase 3 enrollment is complete and late 2026 or early 2027 topline data are expected. That readout directly ties into payers’ growing preference for self administered therapies and could materially influence Briumvi’s addressable MS market. Against that backdrop, the stronger trial results and new schizophrenia program are important, but still secondary, to how the subcutaneous program ultimately plays out.

Yet even with Briumvi’s momentum, investors should be aware of how concentrated revenue exposure can quickly become a liability if...

TG Therapeutics' narrative projects $1.7 billion revenue and $616.2 million earnings by 2029. This requires 33.2% yearly revenue growth and an earnings increase of about $154 million from $461.9 million today.

Uncover how TG Therapeutics' forecasts yield a $51.71 fair value, a 6% downside to its current price.

Exploring Other Perspectives

While consensus focused on Briumvi’s growth potential, the lowest analysts were far more cautious, assuming revenue of about US$1.5 billion and earnings near US$600.9 million by 2029, and a much lower 5.3x PE, so this new clinical news could eventually push those pessimistic expectations closer to the more optimistic view you may have been considering.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.